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Abstract: The rates of type 2 diabetes mellitus, obesity, and cardiovascular disease (CVD) 
continue to increase at epidemic proportions. It has become clear that these disease states are 
not independent but are frequently interrelated. By addressing conditions such as obesity,   
  insulin resistance, stress hyperglycemia, impaired glucose tolerance, and diabetes   mellitus, with 
its micro- and macrovascular complications, a specific treatment strategy can be   developed. 
These conditions can be addressed by early identification of patients at high risk for type 2 
diabetes, prompt and aggressive treatment of their hyperglycemia, recognition of the pleiotropic 
and synergistic benefits of certain antidiabetes agents on CVD, and thus, avoiding potential 
complications including hypoglycemia and weight gain. Incretin-based therapies, which include 
glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-IV (DPP-IV) inhibi-
tors, have the potential to alter the course of type 2 diabetes and associated CVD complications. 
Advantages of these therapies include glucose-dependent enhancement of insulin secretion, 
infrequent instances of hypoglycemia, weight loss with GLP-1 receptor agonists, weight main-
tenance with DPP-IV inhibitors, decreased blood pressure, improvements in dyslipidemia, and 
potential beneficial effects on CV function.
Keywords: cardiovascular disease, glucose control, GLP-1 receptor agonists, DPP-IV 
inhibitors
Introduction
Type 2 diabetes mellitus produces acute and chronic toxicity to vascular endothelium 
in patients as a result of exposure to postprandial glucose (PPG) spikes and continuous 
hyperglycemia. This culminates in the development of microvascular (eg, retinopathy, 
nephropathy, neuropathy) and macrovascular (eg, peripheral vascular disease, 
  myocardial infarction [MI], stroke) complications.1
Damage to blood vessels starts early in the disease process, and as a result, patients 
often present with cardiovascular disease (CVD) and its associated complications 
before actually meeting the diagnostic criteria for type 2 diabetes.2–4 Hyperglycemia 
is a continuous risk factor, with no apparent glycated hemoglobin (HbA1c) threshold 
above which complications begin.5,6 Because type 2 diabetes and CVD are so closely 
interrelated, treatment should focus on the shared pathophysiologic mechanisms of 
the 2 diseases.
This article will review the association between altered glucose metabolism, obesity, 
and CV risk. Current concepts on the pathophysiology of type 2 diabetes and proof 
of concept studies supporting future investigation into the benefits of incretin-based 
therapies on diabetes and CV outcomes will be discussed.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Altered glucose metabolism 
and CVD risk
Clinical studies, including the San Antonio Heart Study,7 the 
West of Scotland Coronary Prevention Study,4 and the Heart 
Outcomes Prevention Evaluation (HOPE) Study,8 have shown 
the complex interplay between CVD, altered glucose metabo-
lism, and obesity. The risk for CVD events (CVD-related 
mortality, MI, stroke) increases across   quintiles of homeo-
stasis model assessment of insulin resistance7; Sattar and 
colleagues4 also demonstrated incrementally increased risk 
for CVD events (hazard ratio [HR] = 1.76; 95%   confidence 
interval [CI], 1.44–2.15) and diabetes (HR = 3.50; 95% CI, 
2.51–4.90) with each additional finding of components of 
the metabolic syndrome. Components of the metabolic syn-
drome included elevated triglycerides (TGs) $ 150 mg/dL, 
lowered high-density lipoprotein cholesterol (HDL-C) , 40 
mg/dL, fasting glucose $110 mg/dL, systolic blood pressure 
(SBP) $130 mm Hg or diastolic BP (DBP) $ 85 mm Hg, and 
body mass index (BMI) . 28.8 kg/m2. Increased waist-to-hip 
ratio and waist circumference all worsen the prognosis for 
men and women with CVD and highlight the importance of 
weight management in patients with CV risk.9
The Diabetes Epidemiology: Collaborative analysis of 
Diagnostic criteria in Europe (DECODE)3 and Whitehall2 
studies have corroborated that the risk of CVD-related 
morbidity and mortality may start significantly before the 
diagnosis of type 2 diabetes. This finding has been reported 
in several studies. In the Cardiovascular Health Study, fast-
ing glucose $115 mg/dL was associated with elevated CVD 
risk (HR = 1.66; 95% CI, 1.39–1.98).10 The Nurses’ Health 
Study showed that risk for CVD began to increase $15 years 
before diagnosis of diabetes (Figure 1).11 The Norfolk study 
(Figure 2) documented a steady increase in CV events cor-
responding to an HbA1c $ 5% in men and $6% in women 
(P , 0.001 for all).12 Haffner and colleagues13 reported 
that patients with diabetes, but with no prior MI, have the 
same risk for an MI as individuals without diabetes, who 
have had a prior MI. This suggests that CV risk factors in 
patients with diabetes need to be identified early and treated 
aggressively.13
In fact, multifactorial intervention aimed at controlling 
all CVD risk factors that may be present in a given patient is 
an important aspect of individualized treatment for patients 
with type 2 diabetes. The Steno-2 study14 randomized 
160 patients with type 2 diabetes, who also had persistent 
microalbuminuria to intensive multifactorial intervention 
(target HbA1c , 6.5%) or conventional therapy. Intensive 
therapy in the Steno-2 study also had goals for fasting 
serum total cholesterol ,175 mg/dL, fasting serum TG 
level , 150 mg/dL, and BP , 130/80 mm Hg. Patients were 
treated with renin – angiotensin system blockers regardless 
of BP and received low-dose aspirin as primary prevention 
for CVD events. Patients in the Steno-2 study were followed 
for a mean of 7.8 years with subsequent follow-up for a mean 
of 5.5 years. The primary clinical end point for the Steno-2 
study was “any cause” time to death at 13.3 years. Twenty-
four patients in the intensive-therapy group died compared 
with 40 in the conventional-treatment group (HR = 0.54; 
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Figure 1 The “ticking clock” hypothesis. Glucose abnormalities increase cardiovascular risk even before the diagnosis of diabetes is made. Multivariate relative risks and 95% 
confidence intervals of myocardial infarction (MI) or stroke according to diabetes status. The Nurses’ Health Study, N = 117,629 women, aged 30–55 years; follow-up 20 
years (1976–1996). Adapted with permission from Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to 
clinical diagnosis of type 2 diabetes. Diabetes Care. 2002;25(7):1129–1134.11 Copyright © 2002 American Diabetes Association.
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Figure 2 Glycated hemoglobin (HbA1c) and heart disease in type 2 diabetes. HbA1c predicts CHD in type 2 diabetes. Rates for total CHD events by category of HbA1c 
concentration and known diabetes in 4,462 men and 5,570 women aged 45–79 years. Adapted with permission from Khaw KT, wareham N, Bingham S, Luben R, welch A, 
Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the european prospective investigation into cancer in Norfolk. Ann Intern Med. 
2004;141(6):413–420.12 Copyright © 2004 American College of Physicians.
Note: aP , 0.001 for linear trend across HbA1c categories.
Abbreviation: CHD, coronary heart disease.
95% CI, 0.32–0.89; P = 0.02). Intensive integrated treat-
ment was also associated with a lower risk of death from 
CVD (HR = 0.43; 95% CI, 0.19–0.94; P = 0.04) and CVD 
events (HR = 0.41; 95% CI, 0.25–0.67; P , 0.001) versus 
conventional treatment.14 The results from the Steno-2 study 
support the view that intensive integrated therapy in high-risk 
patients with type 2 diabetes has the potential to decrease the 
risk for both microvascular and macrovascular complications 
and mortality.
Hospital inpatient considerations 
for glycemia and CVD
The strong correlation between altered glucose metabolism/
hyperglycemia and CVD outcomes has also been reported 
in the critical care setting.15–17 Muhlestein et al16 showed that 
glucose abnormalities are prevalent in patients with coronary 
artery disease and that even mild glucose elevations are 
associated with an increased mortality in patients under-
going percutaneous coronary intervention. Mortality was 
increased .3-fold in patients with fasting glucose concen-
trations .110 mg/dL, underscoring the importance of early 
detection and treatment of hyperglycemia.16 A systematic 
overview found that blood glucose concentrations on hos-
pital admission are an independent predictor of long-term 
morbidity and mortality in patients following an acute MI, 
regardless of diabetes mellitus status. Nondiabetic patients 
with glucose concentrations $6.1–8.0 mmol/L (Table 1; for 
converting mmol/L units to mg/dL units and vice versa in 
this article, see Table 1) had a 3.9-fold (95% CI, 2.9–5.4) 
higher risk of mortality than similar individuals with lower 
Table 1 Conversion table
Convert mmol/L to mg/dL Convert mg/dL to mmol/L
Blood glucose Multiply by 18 Divide by 18 or multiply by 0.055
TC, LDL-C, HDL-C Multiply by 38.67 Divide by 38.67 or multiply by 0.025
Triglycerides Multiply by 88.57 Divide by 88.57 or multiply by 0.011
Abbreviations: TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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glucose concentrations.15 In a prospective study of nondia-
betic patients, 35% of patients admitted to a coronary care 
unit with acute MI developed impaired glucose tolerance 
(IGT) at discharge (95% CI, 28–43) and 40% had IGT (95% 
CI, 32–48) 3 months later. The incidence of newly diagnosed 
diabetes in this population was 31% (95% CI, 24–38) and 
25% (95% CI, 18–32), respectively. These data suggest that 
fasting and postchallenge hyperglycemia might be used as 
early markers of individuals at high risk during the initial 
phase of an acute MI.17
The impact of intensive glycemic control on survival 
in critically ill, hospitalized patients remains unknown due 
to varied study results.18,19 In one study of hyperglycemic 
patients hospitalized for acute MI, glucose normaliza-
tion postadmission was associated with lower mortality. 
This mortality benefit was noted whether or not the patients 
received insulin.18 However, in the Normoglycemia in Inten-
sive Care Evaluation (NICE) and Survival Using Glucose 
Algorithm Regulation (SUGAR) Study, intensive glucose 
control increased mortality in patients in the intensive care 
unit (ICU).19 Patients (N = 6104) who were expected to 
require treatment in the ICU for 3 or more consecutive days 
were randomized within 24 hours of admission to either 
intensive glucose control (target range, 81–108 mg/dL) or 
conventional glucose control (target #180 mg/dL). Death 
occurred in 27.5% of patients in the intensive control group 
and 24.9% in the conventional group (for intensive control, 
odds ratio = 1.14; 95% CI, 1.02–1.28; P = 0.02). Patients 
in the intensive group (6.8%) reported more severe hypo-
glycemia (blood glucose ,40 mg/dL) than patients in the 
conventional group (0.5%, P , 0.001). It remains unclear 
what effect hypoglycemia had on mortality in this study.
Any innovation that would afford intensive, inpatient 
control of glucose without undue hypoglycemia, includ-
ing continuous intravascular glucose monitors, improved 
staff training in use of intensive protocols, and/or the use of 
experimentally validated treatment regimens, may improve 
outcomes in critically ill patients with hyperglycemia.20 More-
over, any pharmacologic therapy that could potentially reduce 
the need for antihyperglycemic agents that increase risk of 
hypoglycemia (ie, sulfonylureas [SFUs], glinides, insulin), 
when treating inpatients with stress/steroid-induced diabetes 
or pre-existing diabetes, should be investigated for its ability 
to reduce morbidity and mortality in this population.
Aggressive glucose lowering
Microvascular and CV risks increase in patients with a longer 
duration of diabetes and a higher HbA1c, with hyperglycemia 
being a continuous risk factor independent of HbA1c level.5,21,22 
Initiation of intensive therapy soon after diabetes is diagnosed 
reduced the risk of microvascular and   macrovascular dis-
eases, with additional benefits seen in patients with HbA1c , 
7%.6,21,23 Patients with a longer duration of diabetes and pre-
existing complications failed to show benefit with an HbA1c of 
∼7% in the Veterans Administration Diabetes Trial (VADT),24 
an HbA1c , 6.5% in the Action in Diabetes and Vascular Dis-
ease: Preterax and Diamicron Modified Release Controlled 
Evaluation (ADVANCE) study,25 and in the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study,26 with an 
actual increased rate of fatal MIs in ACCORD. However, a 
subgroup analysis showed a likely protective effect in patients 
with a shorter duration of diabetes or earlier atheroscle-
rotic disease in VADT22 and reductions in CV outcomes in 
patients in ADVANCE without pre-existing microvascular or 
macrovascular disease and in patients in ACCORD without 
prior CV events (primary prevention) or baseline HbA1c , 
8%. Moreover, in the ACCORD trial, it seems possible that 
unrecognized hypoglycemia and weight gain may have been 
major issues regarding its adverse outcomes.22 In addition, 
data from 2 meta-analyses that include the above studies, 
as well as the United Kingdom Prospective Diabetes Study 
(UKPDS)23 and the PROspective pioglitAzone Clinical Trial 
In macroVascular Events (PROACTIVE) study, showed that 
lower glucose levels reduced MIs and CV events albeit with 
no effect on all-cause mortality.27,28
Currie et al29 published the results of a recent retrospective 
cohort study analyzing survival of patients with type 2 diabetes 
as a function of HbA1c. Two cohorts of patients with type 2 dia-
betes (age, 50 years and older) were analyzed from the United 
Kingdom General Practice Research Database from November 
1986 to 2008. The first cohort included 27,965 patients who 
had treatment intensified from oral monotherapy to combina-
tion oral therapy. The second cohort included 20,005 patients 
who had intensification with an insulin-containing regimen. 
The primary outcome was all-cause mortality. HbA1c was 
broken out by deciles, and survival was analyzed as a function 
of HbA1c decile. For the combined cohorts, compared with 
the HbA1c decile with the lowest HR (median HbA1c, 7.5%; 
interquartile range [IQR], 7.5%–7.6%), the adjusted HR of all-
cause mortality in the lowest HbA1c decile (median, 6.4%; IQR, 
6.1%–6.6%) was 1.52 (95% CI, 1.32–1.76) and in the highest 
HbA1c decile (median, 10.5%; IQR, 10.1%–11.2%) was 1.79 
(95% CI, 1.5–2.06). Results showed a U-shaped curve associa-
tion, with the lowest HR at approximately 7.5%.
In summary, low and high mean HbA1c values were asso-
ciated with increased all-cause mortality and cardiac events, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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and an HbA1c value of approximately 7.5% was associated 
with the lowest all-cause mortality.29 Although these results 
lend support to the findings of ACCORD, the American 
Diabetes Association (ADA) and American Association of 
Clinical Endocrinologists (AACE) glycemic goals are still 
valid and clinicians should strive to reduce HbA1c as low 
as possible for as long as possible, without causing undue 
hypoglycemia and weight gain. Figure 3 is a hypothetical 
representation of the natural history of diabetic subjects 
enrolled in CV outcome studies.30
These data highlight the importance of being able to 
balance the benefits and risks of medications when making 
treatment decisions using antidiabetes agents that minimize 
the risk of hypoglycemia and weight gain, and possibly even 
lead to weight loss.
The new AACE/American College of Endocrinology 
(ACE) guidelines31 emphasized this by recommending oral 
hypoglycemic agents (SFUs/glinides) last, if at all. Early 
use of incretins along with metformin (MET) and thiazoli-
dinediones (TZDs) and early use of combination therapy are 
also recommended.
Thus, based on the pathophysiology of type 2 diabetes and 
its association with increased CVD risk,32 the current goals 
advocated by the ADA, the European Association for the Study 
of Diabetes, and the AACE are to achieve the lowest possible 
HbA1c without undue risk of hypoglycemia and weight gain 
with appropriate individualization. In fact, the ADA has recog-
nized this approach and is supporting a study comparing33 the 
biguanide, MET, the TZD, pioglitazone, and the glucagon-like 
peptide-1 (GLP-1) receptor agonist, exenatide, with treatment 
according to its own guidelines that advocate the use of SFUs 
or early insulin therapy after the failure of MET.34
The role of incretins in the 
pathophysiology of type 2 diabetes
Treatment of patients with type 2 diabetes has traditionally 
focused on improving reduced β-cell function, preventing 
increased peripheral insulin resistance/hepatic gluconeogen-
esis, as well as reducing the rate of absorption of nutrients from 
the gut.35 These issues have been addressed with various hypo-
glycemic and antidiabetic regimens including SFUs, MET, 
TZDs, and α-glucosidase inhibitors. Unfortunately, treatment 
with some of these agents is associated with hypoglycemia, 
weight gain, increased CV risks, and other adverse events.36
It is now known that the pathophysiology of type 2 diabe-
tes is much more complex than previously believed and that 
there are other important mechanisms involved in glucose 
metabolism. Nauck et al37 found differences in β-cell secretory 
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responses between oral and intravenous glucose challenges that 
were attributable to factors other than glycemia (the incretin 
effect). The incretin-based pathway was found to account for 
∼70% of the insulin response to orally ingested glucose.37,38 
The key activities of this pathway occur primarily through the 
actions of 2 intestinal insulin-stimulating hormones: GLP-1 
and glucose-dependent insulinotropic polypeptide (GIP). 
GLP-1 and GIP have various actions in the body, including 
slowing gastric motility, increasing satiety, improving glyce-
mic control, and reducing postprandial fatty acids (Figure 4).39 
For a variety of reasons, GLP-1 has been found to be more 
amenable to therapeutic manipulation than GIP (patients with 
type 2 diabetes are resistant to GIP administration) and, there-
fore, has been the focus of more intensive research.39,40
It has been suggested that a decreased GLP-1 response to 
food may contribute to the progression of type 2 diabetes. This 
was confirmed in a study which reported that meal-stimulated 
GLP-1 response was decreased in patients with type 2 diabetes. 
The authors concluded that this response may contribute to the 
decreased incretin effect seen in patients with type 2 diabetes.41 
Administration of GLP-1 was shown to increase both first- and 
second-phase insulin response,42 improve insulin secretion and 
inhibit glucagon secretion,43 and normalize glucose levels in 
patients with type 2   diabetes.44 In addition, GLP-1-mediated 
effects on insulin and glucagon levels in patients with type 2 
diabetes are glucose-dependent, and exogenous administration 
of GLP-1 does not induce hypoglycemia.45
This characteristic may be a result of GLP-1’s effect on 
the insulin secretion amplification pathway rather than on the 
direct triggering pathway.46–49 Figure 5 depicts the pathways 
for glucose-stimulated secretion of insulin.50
Preclinical studies suggest that there are several poten-
tial pathways of GLP-1-mediated protection of the β-cell, 
including direct effects on signaling cascades that induce 
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β-cell proliferation, increase pancreatic islet regeneration, 
and reduce β-cell apoptosis. These effects may be mediated 
by GLP-1’s influence on the transcription factor pancreas 
duodenum homeobox-1 (PDX-1).51,52 PDX-1 expression 
has been found essential for integrating GLP-1 receptor-
dependent signals, regulating α-cell glucagon secretion, 
and for the growth, differentiated function, and survival of 
islet cells in mice.53 In addition, GLP-1 has been shown to 
counteract the negative effect of steroids on the β-cell secre-
tion of insulin. This may be, in part, related to its effects 
on PDX-1.54 Glucocorticoids, such as dexamethasone, sup-
press pancreatic β-cell gene expression by interfering with 
islet-specific gene enhancers. Dexamethasone has also been 
shown to induce β-cell apoptosis in mouse models, an effect 
reversible with administration of synthetic GLP-1.54
Moreover, GLP-1 seems to overcome steroids’ acute nega-
tive effects, as well as transplant medication effects (eg, calm-
odulin inhibitors)55 on the insulin amplifying pathway.56
In clinical trials, the effects of GLP-1 receptor agonists 
on β-cell function can be measured with surrogate markers 
of insulin secretion and/or homeostasis model assessment 
indices of β-cell function (HOMA-B). Beneficial effects 
of GLP-1 on pancreatic function have been documented in 
clinical studies. In 1 study, plasma glucose concentrations 
were significantly lowered during intravenous infusion of 
GLP-1 in 8 patients with type 2 diabetes and stress hyper-
glycemia following major surgery. Fasting glucose was in 
normal range within 150 minutes but remained elevated 
during placebo infusion (P , 0.001). GLP-1 infusion led to a 
significant increase in insulin secretion (P , 0.001) and sup-
pression of glucagon secretion (P = 0.041), with no reports 
of hypoglycemic events.57 In addition, 1-year treatment 
with exenatide demonstrated improvement in glucose- and 
arginine-stimulated insulin secretion58 while 3-year treatment 
showed sustained HOMA-B improvement.59
Limited data have demonstrated a potential benefit for 
the short-term use of intravenous GLP-1 to be effective 
in patients with stress-induced diabetes (eg, postoperative 
hyperglycemia), especially in patients with prediabetes, or in 
patients with type 2 diabetes that have been treated with prior Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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oral hypoglycemic and antidiabetes therapies. By impacting 
the hyperglycemic effects of glucagon and steroids (2 stress 
hormones), GLP-1 (and agents with incretin effects such as 
the GLP-1 receptor agonists) may be leveraged to decrease the 
need for SFU, glinide, or insulin use in   hospitalized patients, 
and therefore, the potential   development of   treatment-related 
hypoglycemia.60,61
Additional actions and benefits 
of incretins
The pharmacologic actions of GLP-1 extend well beyond 
the pancreas, as GLP-1 receptors have been found in smooth 
muscle cells, cardiac myocytes, endocardium, vascular 
endothelium, and hypothalamus.38,40,62 Improved CV status, 
including enhanced cardiomyocyte viability after ischemia-
reperfusion injury and increased systolic function in preclini-
cal models,63 relaxation of rat conduit arteries,64 and peripheral 
vasodilation in healthy volunteers and patients with type 2 
diabetes,63 and reduction of inflammatory markers63 have 
been demonstrated with GLP-1 administration.
A 72-hour infusion of GLP-1 added to standard therapy 
in acute MI patients with and without diabetes (n = 10) sig-
nificantly improved left ventricular ejection fraction (LVEF) 
(29 ± 2% to 39 ± 2%, P , 0.01) compared with controls 
(n = 11) as measured by echocardiograms after reperfusion 
and after completion of GLP-1 administration.65 CV benefits 
were also seen in patients with congestive heart failure after 
MI, who received 5 weeks of GLP-1 infusion (n = 12). These 
patients showed a significant improvement in LVEF regard-
less of diabetic status (21%–27%, P , 0.001) compared with 
no change in patients on standard therapy alone (21%–22%).66 
Infusion of GLP-1 peri-MI also improved regional functional 
recovery in the peri-infarct zone in humans (n = 10).65 Sokos 
et al67 investigated the effect of a continuous 48-hour infu-
sion of GLP-1 beginning 12 hours before coronary artery 
bypass graft (CABG) surgery in 10 patients with coronary 
heart disease and preserved LV function. This resulted in 
a reduced need for vasopressors, reduced arrhythmias, and 
significantly better glycemic control in the pre- and periop-
erative periods (95 mg/dL vs 140 mg/dL, P # 0.02), with 
45% less insulin requirements to achieve the same level of 
glycemia as in controls (n = 10) in the postoperative period 
(139 mg/dL vs 140 mg/dL).67 Concurrent use of GLP-1 recep-
tor agonists with insulin has not been studied and cannot be 
recommended; however, studies are needed to evaluate their 
efficacy and safety together.
Additional extrapancreatic effects of incretins have been 
reported.38,40 The impact of GLP-1 on gastric emptying has 
been described earlier. The mechanisms responsible for 
the slowing of gastric emptying appear complex and may 
involve activation of signaling mechanisms in both central 
and peripheral nervous system.38,40 Similar mechanisms may 
be responsible for early satiety. Intracerebroventricular and 
peripheral administration of GLP-1 has been shown to inhibit 
food intake in rodents. The GLP-1 receptors affected have 
been localized to the hypothalamic nuclei.38,40 The ability of 
GLP-1 receptor agonists to produce weight loss has been well 
demonstrated in clinical trials.59 Additional effects of GLP-1 
have been reported on the nervous system (antiapoptotic 
effect on neuronal cells), the renal system (natriuresis), and 
the hypothalamic-pituitary axis, but the clinical significance 
of these effects remain undetermined.38
The impact of incretin-based 
therapies on CVD-related  
risk factors
Attempts to limit the use of GLP-1 as a therapeutic agent 
in the treatment of type 2 diabetes have advanced in recent 
years. One of the major barriers to the potential use of 
GLP-1 therapy is its short half-life in the circulation,41 which 
is due largely to its inactivation by the enzyme dipeptidyl 
peptidase-IV (DPP-IV).40 Although GLP-1 is rapidly released 
in response to oral glucose from L cells in the gut, it has a 
half-life of only ∼2 minutes in the circulation and thus con-
tributes to the first-phase insulin response.68 These findings 
led to the development of incretin mimetics, such as GLP-1 
receptor agonists that are resistant to DPP-IV degradation, 
and DPP-IV inhibitors, which inhibit the proteolytic cleavage 
and inactivation of GLP-1.40,41 DPP-IV inhibitors increase the 
concentration of endogenous GLP-1 by ∼2-fold.
GLP-1 receptor agonists
Exenatide was the first incretin mimetic approved by the US 
Food and Drug Administration (FDA). It is a synthetic version 
of the naturally occurring salivary protein of the Gila mon-
ster, exendin-4, which has a 53% sequence identity to human 
GLP-1, is resistant to DPP-IV degradation, and demonstrates in 
vivo binding to human β-cell GLP-1 receptors.40,69 Exenatide is 
indicated as an adjunct to diet and exercise to improve glycemic 
control in adults with type 2 diabetes. Exenatide can be used as 
monotherapy or in combination with MET, SFU, and/or TZD 
and is administered twice-a-day by subcutaneous injection. 
Concurrent use of exenatide with insulin has not been studied 
and therefore cannot be recommended.70
Data from 30-week studies conducted in 963 patients with 
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MET, and combinations of these agents demonstrated that 
the addition of 5 and 10 µg of exenatide was associated with 
significant decreases of −0.60% and −0.86%, respectively, 
from baseline HbA1c (P , 0.002 for all).71–73 Patients treated 
with exenatide also showed progressive, dose-dependent 
weight loss of −1.6 kg (5 µg) and −2.8 kg (10 µg) (P , 0.01 
vs placebo).71–73 Exenatide-treated patients were more likely 
to achieve a HbA1c # 7% (5 µg [27%] and 10 µg [34%]) 
than placebo-treated patients (9%, P , 0.0001).73 The most 
frequently reported adverse events in these studies were 
generally mild or moderate and gastrointestinal in nature; 
no severe hypoglycemia was observed.71–73
The glucose- and weight-reducing effects of exenatide in 
217 patients previously treated with SFU and/or MET have 
been sustained for up to 3 years. Initial reductions in HbA1c 
from baseline to week 30 (−0.9%) were sustained to week 
82 (−1.1%)74 and to 3 years (−1.0%, P , 0.0001)59; 48% of 
patients treated with exenatide achieved HbA1c # 7% at week 
82 and 46% at 3 years.59,74 Exenatide reduced body weight 
from baseline (−2.1 kg) after 30 weeks of treatment, with 
continued reductions observed at week 82 (−4.4 kg)74 and at 
3 years (−5.3 kg, P , 0.0001).59
Data from a number of studies have shown that the addi-
tion of exenatide or insulin glargine or aspart to patients 
with type 2 diabetes and poor glycemic control on SFUs and 
MET is associated with similar reductions in HbA1c (up to 
−1.36%). However, patients gained up to +1.8 kg of weight 
after the addition of insulin but lost up to −2.3 kg of weight 
with exenatide.75–77 Exenatide was also associated with fewer 
instances of hypoglycemia than insulin glargine or aspart.75–77 
Thus, for the same degree of glycemic control, exenatide was 
associated with less hypoglycemia.
Treatment with exenatide was also associated with ben-
eficial effects on other components of CVD risk, including 
dyslipidemia and elevated BP. After 3.5 years of exenatide 
treatment, 217 patients with type 2 diabetes demonstrated a 
12% reduction in TG (−44.4 mg/dL), 5% in total cholesterol 
(−10.8 mg/dL), 6% in low-density lipoprotein cholesterol 
(−11.8 mg/dL), and a 24% increase in HDL-C (8.5 mg/dL) 
from baseline. In addition, both SBP (−3.5 mm Hg) and DBP 
(−3.3 mm Hg) were reduced from baseline values.59
Exenatide has also produced significant improvements 
in CV risk factors, inflammatory cytokines, postprandial 
oxidative stress, and anthropomorphic parameters in patients 
with metabolic syndrome without type 2 diabetes.78–81 
A meta-analysis of patients in the exenatide database showed 
an unadjusted incidence of experiencing $1 CV event was 
2.0% for exenatide and 2.6% for controls (relative risk  =  0.69; 
95% CI, 0.46–1.04).82 Assuming that the apparent reduction 
in CV outcomes is significant and reproducible, it has been 
estimated that use of exenatide over a 10-year period of time 
should result in a 50% decrease in the cumulative incidence 
of MI compared with MET and/or SFUs.83
Transient nausea has been reported in patients treated 
with exenatide in clinical trials. Practicing clinicians 
have learned many techniques to prevent or minimize 
the risk of nausea. One study84 showed that gradual dose 
escalation successfully reduced the proportion of patients 
experiencing dose-limiting nausea and vomiting without 
compromising glycemic control. In the authors’ experi-
ence, patients should inject exenatide with their first bite 
of food and stop eating when they feel full. If patients con-
tinue to eat despite fullness, they may develop bloating and 
gastrointestinal upset, with eventual nausea and vomiting. 
These effects are presumably due to the slowing of gastric 
emptying seen with exenatide.85 Titration of exenatide to 
a dose of 10 µg can occur after 1 month of therapy based 
on clinical response. Patients can delay eating up to 1 hour 
after administration but should take the drug with the first 
bite of a meal to reduce the risk of gastrointestinal upset. 
Patients are likely to lose their appetite between meals 
because of exenatide’s hypothalamic effects to suppress 
appetite.40 This sensation very infrequently develops into 
nausea, which is usually mild in nature, and resolves within 
2 weeks. Occasionally, the nausea can become intoler-
able, which accounts for the withdrawal of 3% of patients 
from clinical studies because of nausea and 1% because 
of vomiting.70
Rare cases of pancreatitis have been reported in patients 
treated with exenatide including fatal and nonfatal hemor-
rhagic or necrotizing pancreatitis. Exenatide postmarketing 
surveillance data are not sufficient to establish a drug-
related causality. Recent reviews have not documented 
an increased risk of pancreatitis with exenatide compared 
with other antidiabetes agents.86,87 However, until more data 
become available, treatment with exenatide should not be 
started in patients with a history of pancreatitis and should 
be discontinued in patients who exhibit symptoms of acute 
pancreatitis. If pancreatitis is confirmed, exenatide should 
not be restarted.70
There have been postmarketing reports of altered 
renal function, including increased serum creatinine, renal 
impairment, worsened chronic renal failure, and acute 
renal failure, sometimes requiring hemodialysis or kidney 
transplantation. Reversibility of altered renal function has 
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discontinuation of the potentially causative agents, including 
exenatide. Exenatide has not been shown to be nephrotoxic 
in preclinical or clinical studies. Exenatide should not be 
used in patients with severe renal impairment (creatinine 
clearance ,30 mL/min).70
Many patients are nervous about getting a subcutaneous 
injection. This fear is often inadvertently instilled by physi-
cians and can often be alleviated through proper education 
in the office.
An extended-release formulation of exenatide, dosed 
once weekly, has been submitted to the US FDA for regu-
latory review. Treatment with exenatide once weekly has 
been associated with improved HbA1c, BP, and lipid levels 
in patients with type 2 diabetes.88,89 After 30 weeks of treat-
ment, exenatide once weekly produced significantly greater 
changes in HbA1c than exenatide BID (−1.9% vs −1.5%, 
P = 0.0023), with a significantly greater proportion of 
patients achieving target HbA1c # 7% (77% with exenatide 
once weekly vs 61% with exenatide BID, P = 0.0039).89 
One year of treatment with exenatide once weekly resulted 
in improvements in HbA1c (−2.0%), weight (−4.1 kg), and 
SBP and DBP (6.2 mm Hg and 2.8 mm Hg, respectively from 
baseline; P , 0.05).88 Exenatide once weekly is associated 
with a reduced risk for nausea.
Reductions in fasting blood glucose and PPG with the 
first treatment injection could make exenatide once weekly 
an ideal therapy to administer to patients prior to hospital 
admission (ie, for surgery), to treat stress hyperglycemia 
with likely improved glycemic control and a decrease in 
in-hospital hypoglycemia. Because of its extended effects 
on blood glucose levels, exenatide once weekly should be 
investigated for its ability to treat patients prior to hospital 
admission.
Liraglutide, another GLP-1 receptor agonist, is 97% 
homologous to GLP-1 with an acyl moiety that promotes 
noncovalent binding to albumin. This reduces its degrada-
tion by DPP-IV , prolongs its half-life to ∼13 hours, and 
allows for once-daily administration.69,90,91 Liraglutide has 
been approved for use as an adjunct to diet and exercise to 
improve glycemic control in adults with type 2 diabetes. It 
is not recommended as first-line therapy for patients inad-
equately controlled with diet and exercise. It can be used as 
monotherapy or in combination with MET, a SFU, or a TZD. 
The concurrent use of liraglutide and insulin has not been 
studied.92 Liraglutide has also been approved in the European 
Union for adjunctive use in patients with type 2 diabetes 
and inadequate glycemic control with MET, SFU, MET and 
SFU, or MET and TZD combination therapy. Liraglutide is 
administered once daily via subcutaneous injection.92 In the 
Liraglutide Effect and Action in Diabetes (LEAD) studies, 
treatment with liraglutide (doses up to 1.8 mg) was associated 
with equivalent or greater improvements in HbA1c and weight 
than comparator treatments including MET, combination of 
MET and SFU or TZD, and combination of MET, SFU, and 
insulin glargine.90,93–97 The LEAD studies also showed that 
liraglutide was associated with improvements in SBP and 
DBP.96,98–101
In clinical trials, liraglutide therapy has been associ-
ated with pancreatitis. Eight cases were reported during 
intermediate- and long-term trials in the liraglutide clinical 
development program. Seven of the cases were in patients 
treated with liraglutide and 1 case in a patient receiving a 
comparator. Of the 7 cases in liraglutide-treated patients, 5 
were reported as acute pancreatitis and 2 were reported as 
chronic pancreatitis. There is no conclusive data establish-
ing a risk of pancreatitis with liraglutide. After initiation of 
liraglutide, and after dose increases, clinicians should observe 
patients carefully for signs and symptoms of pancreatitis. If 
pancreatitis is suspected, liraglutide and other potentially 
suspect agents should be discontinued. If pancreatitis is 
confirmed, liraglutide should not be restarted.92
Liraglutide has a “box” warning in its full prescribing 
information for the risk of thyroid C-cell tumors in humans. 
The warning is as follows: liraglutide causes thyroid C-cell 
tumors at clinically relevant exposures in rodents. It is unknown 
whether liraglutide causes thyroid C-cell tumors, including 
medullary thyroid carcinoma (MTC), in humans as human 
relevance could not be determined by clinical or nonclinical 
studies.92 The basis for this warning arises from carcinogenicity 
studies that showed proliferative changes in the C-cells of the 
thyroid gland in rodents receiving liraglutide. These prolifera-
tive changes included benign and malignant C-cell neoplasia 
(eg, MTC) and were dose-dependent and treatment-duration-
dependent.92 Serum calcitonin is a biomarker of MTC. As a 
result of the findings in rodents, serum calcitonin levels were 
measured during clinical trials with liraglutide. At weeks 26 
and 52 in clinical trials, adjusted mean serum calcitonin 
levels were higher in liraglutide-treated patients than placebo 
patients, but were not higher than patients receiving active 
comparator. There have been no clear-cut cases of MTC in 
patients treated with liraglutide. Liraglutide-treated patients 
who develop elevated serum calcitonin levels or thyroid 
nodules on physical examination or neck imaging should be 
referred to an endocrinologist for further evaluation.92
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include taspoglutide and albiglutide. Taspoglutide has been 
shown to reduce HbA1c (up to −1.2%) and weight (up to 
−2.8 kg) when added to MET,102 and albiglutide reduced 
fasting plasma glucose (FPG) and postprandial concentra-
tions in patients with type 2 diabetes.103
DPP-IV inhibitors
Sitagliptin is the first US FDA-approved DPP-IV inhibitor. 
It has been shown to stimulate glucose-dependent insulin 
secretion and inhibit glucagon secretion, as well as mitigate 
fasting and PPG concentrations and reduce elevated HbA1c. 
Treatment with orally administered sitagliptin has demon-
strated efficacy with a once-daily dosage regimen.104 After 
18 weeks of treatment in 521 patients with type 2 diabetes, 
HbA1c was significantly reduced with sitagliptin (100 and 
200 mg) compared with placebo (placebo-subtracted HbA1c 
reduction, −0.60% and −0.48%, respectively). Sitagliptin also 
improved FPG, HOMA-B, and fasting proinsulin:insulin ratio 
but had a neutral effect on body weight.
The incidence of hypoglycemia did not differ sig-
nificantly between sitagliptin and placebo.105 In a 24-week 
study, the addition of sitagliptin to MET in 1,091 patients 
with type 2 diabetes was associated with placebo-subtracted 
HbA1c changes from baseline up to −2.07% (P , 0.001 for 
comparisons vs placebo and coadministration vs respective 
monotherapies). The incidence of hypoglycemia was low 
(0.5%–2.2%) across active treatment groups and did not 
differ significantly from placebo (0.6%).106
In another study of 441 patients, the addition of sitagliptin 
to glimepiride ± MET reduced HbA1c by −0.74% (P , 0.001) 
versus placebo after 24 weeks. The addition of sitagliptin 
reduced FPG by −20.1 mg/dL (P , 0.001) and increased 
HOMA-B by 12% (P , 0.05) relative to placebo. Weight 
and incidences of hypoglycemia increased in the sitagliptin 
treatment group compared with placebo (+0.8 vs −0.4 kg; 
P , 0.001 and 12% vs 2%, respectively).107
Saxagliptin is another DPP-IV inhibitor that has received 
US FDA approval. In addition to its glucose-lowering potential, 
saxagliptin may also have some cardioprotective effects.108 
An analysis of 8 randomized, double-blind, phase IIb/III tri-
als, involving 3,356 subjects randomized to saxagliptin and 
1,251 subjects randomized to comparator, showed no increased 
CV risk with saxagliptin as monotherapy or in combination. 
The data raise the possibility of a cardioprotective effect that 
requires further study.108 Other DPP-IV inhibitors in clinical 
development include alogliptin109 and vildagliptin (which is 
currently available in the European Union and Latin America 
but has not been approved in the United States).
In clinical studies, DPP-IV inhibitors have been associated 
with improvements in BP, dyslipidemia, and inflammatory 
cytokine levels but have not been shown to accelerate weight 
loss in patients with type 2 diabetes.110–112 DPP-IV therapy 
has been associated with an increased incidence of upper   
  respiratory infections, nasopharyngitis, and headache. Other 
rare, but more serious, adverse events include hypersensitivity 
reactions and anaphylaxis.110,113 Postmarketing surveillance 
shows that between October 16, 2006 and February 9, 2009, 
88 cases of acute pancreatitis were reported to the US FDA 
in association with sitagliptin therapy, including 2 cases of 
hemorrhagic or necrotizing pancreatitis. The manufacturer 
has been asked to update their product labeling as a result 
of these spontaneous case reports.114
GLP-1 receptor agonists versus 
DPP-IV inhibitors
The effects of exenatide and sitagliptin were compared in 
a 2-week study in which 61 patients with type 2 diabetes 
received 5 µg BID of exenatide subcutaneously for 1 week, 
then 10 µg for 1 week, or 100 mg of oral sitagliptin every 
morning for 2 weeks. Patients crossed over to the alternate 
therapy after 2 weeks of treatment. Exenatide had a signifi-
cantly greater effect in reducing 2-hour PPG concentration 
(133 mg/dL) than sitagliptin (208 mg/dL, P , 0.0001), 
although the effects of both agents in reducing FPG was 
similar. Exenatide also significantly improved the insulino-
genic index of insulin secretion (1.50, P = 0.0239), reduced 
postprandial glucagon secretion (0.88, P = 0.0011), slowed 
gastric emptying (0.56, P , 0.0001), and reduced total caloric 
intake (−134 kcal vs +130 kcal, P = 0.0227) compared with 
sitagliptin.85 An additional comparative study is ongoing, 
which will provide more information to clinicians, who must 
select the right drug for the appropriate patient, matching 
drug and patient characteristics.
Investigational incretin use 
perioperatively: CABG
To reap the potential acute benefits of incretin use peri-
operatively as suggested by studies with GLP-1 used in 
surgery,61 including the possibility of avoiding the use of 
hypoglycemic agents postoperatively (especially in patients 
not previously known to have diabetes or only requiring 
prior oral therapy for diabetes preadmission), incretins 
have been used in surgery including CABG and open-
heart surgery (Table 2). Our experience at the University 
of Pennsylvania in ∼100 patients has shown that sitagliptin 
is well tolerated and is equal to ∼20 U of insulin, whereas Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Table 2 Perioperative glycemic guidelines used at the University of Pennsylvania
Medications Identify  
patient
Preoperative 
day
Operative  
day
Postoperative 
day 1−x
Until  
discharge
Preadmin In-hospital
CABG/
operations 
requiring 
insulin drips
At risk,  
HbA1c ∼5.8  
and .
Non-diabetes 
mellitus
iv insulin drip √ √ (until am day 3)
incretina Start √
SFU/Pio/MeT  
as below
√
CF fast-analog √ (when off drip) √
IFG/IGT/DM
incretina √ or start √ √ √
SFU/glinide √ X X Consider
Piob √ √ √
MeTc X X X Only if stable
iv insulin drip √ √ (stop am day 3)
Basal insulin
Bolus insulin if normal PO- may 
not need if on  
incretin
if normal PO
CF fast-analog √ (when off drip) √
Non-CABG
Non-diabetes 
mellitus
Postoperative  
bloodglucose >180
Postoperative blood 
glucose >180
incretin Start
SFU/Pio/MeT as 
below
√
CF aspart √ √
IFG/IGT/DM
incretina √ or start √ √ √ √
SFU/glinide √ X X Consider
Piob √ X √ √
MeTc X X X Only if stable
Basal insulin √ √ √ √
Bolus insulin if normal meals if normal PO-may 
not need if on  
incretin
if normal 
meals
CF fast-analog √ √
Notes:  aIncretin  administration:  exenatide  may  be  administered  when  patient  is  either  NPO  or  PO  (when  operative-associated nausea  is  gone).  DPP-IV  inhibitors 
administered only when patient is PO. bPioglitazone can only be administered if the patient does not have a history of congestive heart failure. cMetformin Cr , 1.5 male, 
,1.4 female, age ,70 years.
Abbreviations: CABG, coronary artery bypass graft; HbA1c, glycated hemoglobin; iv, intravenous; SFU, sulfonylurea/glinide; Pio, pioglitazone; MeT, metformin; CF, 
correction factor; iFG, impaired fasting glucose; iGT, impaired glucose tolerance; DM, diabetes mellitus; PO, per oral; DPP-iv, dipeptidyl peptidase-iv inhibitor; NPO, nothing 
by mouth; X, not given; √, given.
exenatide is equal to ∼40 U of insulin. According to a writ-
ten communication from G. Umpierrez (January 13, 2010), 
when one stops insulin drips on day 3 using post-CABG 
insulin drip protocols, most patients with drip rates ,2.5 
U/h for the last 6 hours do quite well with sitagliptin alone. 
Though there has been some concern about perioperative 
nausea with exenatide, this has occurred infrequently since 
only ∼1% of patients have a hypothalamic super sensitivity 
to the agent. Clinically reported nausea is predominantly 
related to eating after feeling “full.” As most patients have 
less food intake following surgery, nausea after surgery has 
not been a significant issue.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Conclusion
Current guidelines from the ADA advocate SFU use early 
in the diabetes disease process. The ADA only recommends 
GLP-1 receptor agonists (eg, exenatide) if there are concerns 
about the development of hypoglycemia or weight gain. 
Given the detrimental effects of these variables on CVD 
and further glycemic control, it seems very prudent to take 
these factors into account when considering antidiabetes 
agents. Thus, guidelines that avoid the use of oral antidi-
abetes agents associated with hypoglycemia and weight gain 
(eg, AACE/ACE algorithm) are more logical and becoming 
increasingly popular in treating patients with diabetes, even 
perioperatively.
Type 2 diabetes and CVD share many pathophysiologic 
nuances as they continue to grow at epidemic rates. Since 
these conditions are interrelated, optimized treatment strate-
gies for patients with type 2 diabetes should not only focus 
solely on hyperglycemia but also address other CVD risk 
factors, including overweight/obesity, elevated BP, and dys-
lipidemia. The results of studies such as Steno-2 highlight 
the importance of controlling all CV risk factors in patients 
with type 2 diabetes. The confusing results from outcome 
studies that examined these variables in patients with type 
2 diabetes, such as ACCORD, ADVANCE, and NICE-
SUGAR, may be secondary to the use of nonideal hypogly-
cemic agents (eg, SFUs in ADVANCE).   Moreover, therapies 
that increase hypoglycemia and weight (ACCORD) and thus 
suggest increased fatal MIs should not lead to glycemic 
therapeutic nihilism. As vascular damage accrues early in 
the type 2 diabetes disease process and is directly related 
to the abnormal metabolic environment/hyperglycemia, 
the addition of incretin-based therapies to the antidiabetes 
agent armamentarium offers strong potential for treatments 
that work on the underlying defects of type 2 diabetes by 
decreasing glycemic levels without hypoglycemia, and 
while reducing weight and CV risk factors. Clinical data 
continues to accumulate supporting the use of incretin-
based therapies as optimal therapy for glucose lowering, 
as well as for reducing the risk of CVD-related morbidity 
and mortality, although more data, particularly on CV 
outcomes, is required.
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